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Background: Antibodies to non-pathogenic rabbit caliciviruses (RCVs) cross-react in serological tests for rabbit
hemorrhagic disease virus (RHDV) and vice versa, making epidemiological studies very difficult where both viruses
occur. It is important to understand the distribution and interaction of the two viruses because the highly
pathogenic RHDV has been used as a biocontrol agent for wild rabbits in Australia and New Zealand for the past
17 years. The presence of the benign RCV Australia 1 (RCV-A1) is considered a key factor for the failure of RHDV
mediated rabbit control in cooler, wetter areas of Australia.
Results: A highly sensitive and specific blocking ELISA was developed for the detection of RCV-A1 antibodies.
When sera from rabbits with a known infection history for either RCV-A1 or RHDV were tested, this assay showed
100% sensitivity and no cross-reactivity with RHDV sera (100% specificity).
Conclusions: This new ELISA not only allows the detection of RCV-A1 at a population level, but also permits the
serological status of individual rabbits to be determined more reliably than previously described methods. This
robust and simple to perform assay is therefore the tool of choice for studying RCV-A1 epidemiology in Australian
wild rabbit populations.
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Rabbit calicivirus (RCV) and rabbit hemorrhagic disease
virus (RHDV) are positive sense single stranded RNA
viruses in the genus Lagovirus of the family Caliciviridae
[1-4]. The non-pathogenic RCVs are of great interest be-
cause they are believed to induce cross-protection to the
closely related but highly pathogenic RHDV that is used
as a biocontrol agent for wild rabbits in Australia and
New Zealand [5-11]. RHDV caused mortality rates as
high as 95% in dry, warm areas of the Australian contin-
ent, but failed to be as effective in wetter, cooler areas
[6,12]. The known distribution of a benign calicivirus,
RCV-A1, isolated from Australian wild rabbits has so far
been consistent with areas where RHDV is less effective
[13,14]. The partial cross-protection of RCV-A1 against
RHDV was confirmed in experimental infections of do-
mestic rabbits [15], highlighting the need to study the* Correspondence: tanja.strive@csiro.au
1Commonwealth Scientific and Industrial Research Organisation, Ecosystem
Sciences Division, GPO Box 1700, Canberra ACT, 2601, Australia
2Invasive Animals Cooperative Research Centre, University of Canberra,
Canberra, Australia
© 2012 Liu et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the orinteraction between the two viruses in wild rabbit popu-
lations. In Europe, the situation is reversed as rabbits are
considered an important part of local ecosystems [16],
and the attractive potential of using non-pathogenic
RCVs as natural vaccines for conservation of wild rabbit
populations makes epidemiological studies of such be-
nign caliciviruses of interest.
Caliciviruses have a well conserved capsid morphology
[17]. The amino acid identity of the capsid protein VP60
of RCV and RHDV varies between 86.8% and 91.5%, and
there is strong serological cross-reactivity between
RHDV and RCVs [6,14,18-21]. Wild rabbit populations
in Australia known to be infected with RCV-A1 are also
regularly exposed to RHDV, meaning that many wild
rabbits have antibodies (Abs) to both viruses. Due to the
antigenic similarity and the resulting cross-reactive Abs
to the two viruses, studying the seasonal dynamics of
one virus in the presence of the other has proved very
challenging in the past [10,11,22,23].
Enzyme-linked immunosorbent assays (ELISAs) for the
detection of RHDV Abs have been used for many years
[2,24], and certain patterns of cross-reactivity of RCV-A1This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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RCV-A1 serology [7]. However, ELISAs for the specific de-
tection of RCV-A1 Abs were only recently developed
[14,25]. As expected, in the highly sensitive RCV-A1 iso-
type ELISAs for the detection of IgG, IgA and IgM, sera
raised against RHDV showed varying levels of cross-re-
activity, while a competition ELISA (cELISA-2) for RCV-
A1 showed 100% specificity and 76% sensitivity. The
cELISA-2 is a useful tool to detect the presence of RCV-
A1 at a population level but the low sensitivity means that
a large number of samples must be tested to confirm the
absence of RCV-A1 [25]. It is therefore of limited value for
monitoring the serological status of individual rabbits.
The aim of this study was to develop a more sensitive
ELISA that is still highly specific for the detection of
RCV-A1 Abs.Methods
The production of reagents including RCV-VLP (virus-
like particles), anti-RCV-A1 chicken polyclonal anti-
bodies (pAb) and mouse monoclonal antibodies (mAb)
has been described previously [25]. Sera from domestic
New Zealand white rabbits with a known infection his-
tory (RCV-1 to RCV-25, RHDV-1 to RHDV-9) [25] were
diluted at 1:10, 1:40, 1:160 and 1:640 in PBS-TY buffer
[pH 7.4, PBS with 0.05% Triton X-100 (v/v) and 1% yeast
extract (w/v)] for testing.
All ELISAs were carried out in high-binding 96-well
microtitre ELISA plates (Serial No. 655061, Greiner Bio-
One). Reagents were diluted in PBS-TY buffer for incu-
bation. Unless otherwise stated, incubations were carried
out for 1 h at 37°C. After each incubation step, plates
were washed 3 times with PBST (PBS with 0.05% Triton
X-100) by shaking at 150 rpm for 5 min at room
temperature for each washing step. All reagents were
added in 50 μl volumes, and the specified concentrations
are final concentrations.
The blocking ELISA was performed as follows. The plate
was coated with chicken pAbs to RCV-A1 (2.0 μg/ml)Figure 1 Design of the blocking ELISA. (A) The five components of the
chicken IgY is used for coating; (B) Negative result: negative rabbit serum d
antibody gives 100% signal; (C) Positive result: RCV specific antibodies in ra
resulting in inhibition of the signal.diluted in carbonate buffer (pH 9.6) at 4°C overnight.
RCV-VLPs were added and incubated, followed by addition
of serially diluted rabbit sera. After incubation and wash-
ing, anti-RCV-A1 mAb 11F12 was added and incubated.
After washing, goat anti-mouse IgG-HRP (horseradish per-
oxidase) (1.0 μg/ml, Abcam, Cambridge) was added and
incubated. After washing, 50 μl of phosphate-citrate buffer
(pH 5.0) containing O-phenylenediamine dihydrochloride
(Sigma-Aldrich) at 0.5 mg/ml and H2O2 at 0.02% (v/v) was
added. After 5 min incubation at room temperature, the
reaction was stopped with 50 μl of 2 M H2SO4, and the op-
tical density (OD) at 492 nm was measured on a Multiskan
Ascent plate reader (Thermo Labsystems). The OD of the
negative serum was set to 100%, and the percentage of in-
hibition of tested sera was calculated as (Inhibition)
%= [(OD of negative serum – OD of tested serum)/OD of
negative serum]×100% at the respective dilution. The
positive cut-off was set at 25% (see below). Titres are the
reciprocal of the final dilution causing >25% inhibition.
All procedures involving production of sera in rabbits
were conducted according to the Australian code of
practice for the care and use of animals for scientific
purposes and were approved by the CSIRO Sustainable
Ecosystems Animals Ethics Committee (SEAEC no. 07-
01, 08-02, 09-10 and CESAEC no.10-13).Results and discussion
The setup of this blocking ELISA is shown in Figure 1.
Negative rabbit serum will not block the binding of the
RCV-A1 specific mAb 11F12 to RCV-VLP, resulting in a
positive signal (Figure 1B). When positive RCV-A1
serum is added, the RCV-A1 specific Abs binding to the
same epitope as mAb 11F12 will block the binding of
mAb 11F12 and the OD is thus reduced (Figure 1C).
Among the four reagents used in this blocking ELISA,
the concentration of the antigen, RCV-VLP, is the key
factor for the sensitivity and specificity of the assay, and
the mAb 11F12 and the commercially available anti-
mouse IgG-HRP should be used at concentrations thatassay are added in succession according to their number. Anti-RCV
oes not bind to RCV-VLP and shows no inhibition, so the monoclonal
bbit serum bind to the same epitope as the RCV-A1 specific mAb,
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sites. To find the optimal concentrations of RCV-VLP
and mAb 11F12 for this assay, serially diluted RCV-VLP
and mAb 11F12 were tested by using negative rabbit
serum at a dilution of 1:100 (Figure 2). When RCV-VLP
was used at 2.5 μg/ml, a plateau occurred when the con-
centration of mAb 11F12 was higher than 0.33 μg/ml,
indicating 0.33 μg/ml of mAb is sufficient to saturate
2.5 μg/ml of RCV-VLP. In the plateau phase, the nega-
tive serum gave an OD between 1.0 ~ 1.2. In the final
setup of this blocking ELISA, RCV-VLP and mAb 11F12
were used at 2.5 μg/ml (1:1500) and 0.33 μg/ml (1:4000),
respectively. The secondary Ab was optimised by testing
serial dilutions.
The rationale for choosing this concentration for
RCV-VLP is that using more RCV-VLP will reduce the
sensitivity of the assay because a higher concentration of
RCV-specific Abs in rabbit serum is needed to show in-
hibition. On the other hand, if less RCV-VLP is used,
the negative serum gives a lower OD and some RHDV
sera may cause inhibition due to cross-reactive Abs. The
mAb 11F12 is specific for RCV-A1 and does not cross-
react with RHDV [25] thus inhibition by RHDV sera is
most probably due to steric hindrance or conformational
changes induced by the binding of cross-reactive Abs to
other epitopes adjacent to the epitope specific for mAb
11F12.
To determine the cut-off of this blocking ELISA, sera
from domestic rabbits known to be immune to either
RCV-A1 (n = 22) or RHDV (n = 9) [25] were tested.
When diluted at 1:10, all the RCV-A1 sera showed in-
hibition higher than 40%, while the inhibitions of the
RHDV sera were 10% or lower at the same dilution
(Table 1). This assay was repeated three times with the
same RCV-A1 and RHDV sera and similar results were
obtained. To avoid possible “false-positive” results from
RHDV sera, the cut-off of this assay has to be higher
than the reduction of OD caused by the cross-reactiveFigure 2 Optimization of the key reagents for the blocking
ELISA. To determine the optimal concentrations of RCV-VLP and
monoclonal antibody 11F12, RCV-VLP and 11F12 were serially
diluted and a negative serum was tested at dilution of 1:100.Abs in RHDV sera. For this blocking ELISA, a 25% re-
duction of OD compared with negative serum at the re-
spective dilution was regarded as positive.
To compare the sensitivity and specificity of this assay
to the previously published RCV-A1 cELISA-2 [25], the
above sera were tested by endpoint titration. Using the
same cut-off (25%), the cELISA-2 failed to detect six of
the low level Ab responses to RCV-A1 (underlined in
Table 1), while all 22 RCV-A1 sera tested positive in the
blocking ELISA, demonstrating the increased sensitivity
of this assay. Interestingly, the ELISA titres were not al-
ways higher in the blocking ELISA when compared to
the cELISA-2. While two- to four-fold changes in ELISA
titres between assays are not unusual, the differences in
titres for sera RCV-17 and RCV-22 for example cannot
be explained by this. Sera RCV-17 and RCV-22 were
sampled 27 and 39 days post infection, respectively [25].
It is feasible that some sera from animals with mature
immune responses that have a high proportion of high
avidity antibodies to the same or overlapping epitopes to
the detecting mAb, may have an advantage at higher
dilutions in the cELISA-2 setup. The specificity of the
blocking ELISA was 100% as all RHDV sera (n = 9)
tested negative.
To confirm the specificity of the assay, sera from wild
rabbits naturally infected with RHDV (n = 25) were
tested at dilutions of 1:10, 1:40 and 1:160. These samples
were all positive to RHDV (Table 1), and were sourced
from populations that were known to be free from RCV-
A1 by analysing a large number of samples (n > 20) with
the RCV-A1 cELISA-2 (data not shown). They all tested
negative in the blocking ELISA. Three RHDV sera
(RHDV-W19, W21 and W23) showed inhibitions be-
tween 20%~ 23% at a 1:10 dilution. To compare the di-
lution profiles between low titre RCV sera and RHDV
sera from wild rabbits, we first diluted three RCV sera
(RCV-17, RCV-18 and RCV-21) in negative serum to
produce an inhibition of 25 – 35%, and then compared
these diluted RCV sera with sera from wild rabbits.
When compared to RCV-A1 sera, the inhibition levels
of RHDV sera from wild rabbits were only slightly
reduced following serial dilution (Figure 3), indicating
that the inhibition was likely due to non-specific bind-
ing. To avoid doubtful or false positive results, we there-
fore recommend that three dilutions of rabbit serum
should be tested for the routine detection of RCV-A1
Abs.
The blocking ELISA is much more robust and easier
to perform than the cELISA-2 [25]. In the cELISA-2,
pre-mixing of rabbit serum with the RCV-A1 specific
mAb is necessary, or the addition of rabbit serum has to
be followed immediately by the addition of mAb, to pro-
vide an equal opportunity for Abs in the rabbit serum
and the mAb to bind to the antigen. When testing large
Table 1 Comparison of RCV blocking ELISA (bELISA) and
competition ELISA (cELISA)
Sample ID Inhibition at
dilution
of 1:10 (%)a
RCV bELISA
titre
RCV cELISAb
titre
RHDV cELISAb
titre
RCV-1c 57 160 640 0
RCV-2 56 160 160 0
RCV-3 65 160 40 0
RCV-4 60 320 160 80
RCV-8 42 40 80 0
RCV-9 62 160 320 0
RCV-10 56 160 0 0
RCV-11 72 160 40 0
RCV-12 63 160 20 0
RCV-13 50 160 0 0
RCV-14 51 160 0 0
RCV-15 53 160 0 0
RCV-16 71 160 640 0
RCV-17 59 80 640 0
RCV-18 70 160 80 0
RCV-19 61 160 80 0
RCV-20 43 40 0 0
RCV-21 55 40 0 0
RCV-22 58 40 640 0
RCV-23 66 160 160 0
RCV-24 74 320 160 0
RCV-25 66 160 320 0
RHDV-1 6 0 0 320
RHDV-2 0 0 0 81,960
RHDV-3 0 0 0 20,480
RHDV-4 10 0 0 640
RHDV-5 0 0 0 160
RHDV-6 0 0 0 160
RHDV-7 2 0 0 160
RHDV-8 2 0 0 320
RHDV-9 2 0 0 640
RHDV-W1d 7 0 0 80
RHDV-W2 1 0 0 80
RHDV-W3 1 0 0 320
RHDV-W4 1 0 0 80
RHDV-W5 1 0 0 160
RHDV-W6 0 0 0 160
RHDV-W7 6 0 0 80
RHDV-W8 6 0 0 320
RHDV-W9 5 0 0 80
RHDV-W10 8 0 0 40
RHDV-W11 7 0 0 40
Table 1 Comparison of RCV blocking ELISA (bELISA) and
competition ELISA (cELISA) (Continued)
RHDV-W12 0 0 0 160
RHDV-W13 0 0 0 640
RHDV-W14 3 0 0 320
RHDV-W15 12 0 0 320
RHDV-W16 6 0 0 320
RHDV-W17 13 0 0 160
RHDV-W18 12 0 0 320
RHDV-W19 23 0 0 640
RHDV-W20 7 0 0 80
RHDV-W21 20 0 0 320
RHDV-W22 14 0 0 640
RHDV-W23 22 0 0 320
RHDV-W24 8 0 0 320
RHDV-W25 12 0 0 320
aThe inhibition of sera tested at dilution of 1:10 in the blocking ELISA when
RCV-VLP was used at 2.5 μg/ml (1:1500) and 0.33 μg/ml (1:4000), respectively.
bRCV cELISA and RHDV cELISA were performed according to the RCV and
RHDV cELISA-2 in Liu et al. [25]. cData for RCV cELISA and RHDV cELISA of sera
RCV-1 to RHDV-9 are from Liu et al. [25] for comparison. dSera RHDV-W1 to
W25 were sampled from wild rabbit populations proven to be free of RCV-A1
by quantitative PCR and serological tests.
Liu et al. Virology Journal 2012, 9:182 Page 4 of 5
http://www.virologyj.com/content/9/1/182numbers of samples, serially diluting and pre-mixing of
each rabbit serum with mAb is very time-consuming
and, adding rabbit serum and mAb into the same well
within a short period of time can be technically challen-
ging. In contrast, the blocking ELISA separates these
two steps, resulting in an assay that is much more suit-
able for high throughput analysis.
In summary, this highly sensitive, specific and easy to
perform blocking ELISA for RCV-A1 represents a new
serological tool for epidemiological studies of RCV-A1.Figure 3 Titration curves of RCV-A1 and RHDV sera from
rabbits in the blocking ELISA. RCV-17, 18, 21: sera from domestic
rabbits infected with RCV-A1. These sera were first diluted with
negative serum to produce inhibition levels of 25 – 35%. RHDV-W7 -
W23: sera from wild rabbits naturally infected with RHDV showed
low levels of cross reactivity. All sera were tested at dilutions of 1:10,
1:40 and 1:160 in PBS-TY.
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RCV-A1 antibodies in rabbits at both population and in-
dividual levels.
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